Spring Bank Pharmaceuticals, Inc. (SBPH) Given Average Recommendation of “Buy” by Brokerages

Shares of Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) have received a consensus recommendation of “Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $26.33.

A number of brokerages recently issued reports on SBPH. Cantor Fitzgerald set a $29.00 price target on shares of Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 16th. Chardan Capital restated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, November 6th. B. Riley assumed coverage on shares of Spring Bank Pharmaceuticals in a research note on Monday, November 6th. They issued a “buy” rating and a $30.00 price objective on the stock. ValuEngine cut shares of Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Finally, Dawson James reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th.

Several hedge funds and other institutional investors have recently bought and sold shares of SBPH. DAFNA Capital Management LLC purchased a new position in Spring Bank Pharmaceuticals in the second quarter valued at about $217,000. C WorldWide Group Holding A S purchased a new stake in shares of Spring Bank Pharmaceuticals during the second quarter worth about $340,000. EAM Investors LLC purchased a new stake in shares of Spring Bank Pharmaceuticals during the second quarter worth about $578,000. Vanguard Group Inc. acquired a new stake in shares of Spring Bank Pharmaceuticals during the second quarter worth about $794,000. Finally, Morse Asset Management Inc lifted its holdings in shares of Spring Bank Pharmaceuticals by 156.9% during the second quarter. Morse Asset Management Inc now owns 63,700 shares of the company’s stock worth $862,000 after purchasing an additional 38,900 shares during the period. Hedge funds and other institutional investors own 29.70% of the company’s stock.

Shares of Spring Bank Pharmaceuticals (SBPH) traded up $0.24 during trading on Friday, reaching $14.04. 24,000 shares of the company were exchanged, compared to its average volume of 33,880. Spring Bank Pharmaceuticals has a 52 week low of $6.31 and a 52 week high of $18.93.

WARNING: “Spring Bank Pharmaceuticals, Inc. (SBPH) Given Average Recommendation of “Buy” by Brokerages” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/01/spring-bank-pharmaceuticals-inc-sbph-given-average-recommendation-of-buy-by-brokerages.html.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Analyst Recommendations for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply